Mirae Asset Global Investments Co. Ltd. Purchases 1,050,244 Shares of Gilead Sciences, Inc. $GILD

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,050,244 shares of the biopharmaceutical company’s stock, valued at approximately $156,539,000. Mirae Asset Global Investments Co. Ltd. owned approximately 0.08% of Gilead Sciences at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of GILD. Investment Partners LTD. increased its holdings in shares of Gilead Sciences by 5.4% in the 3rd quarter. Investment Partners LTD. now owns 4,084 shares of the biopharmaceutical company’s stock valued at $609,000 after acquiring an additional 211 shares during the last quarter. Blue Fin Capital Inc. acquired a new stake in shares of Gilead Sciences during the 3rd quarter valued at approximately $201,000. Summit Global Investments raised its position in shares of Gilead Sciences by 41.3% during the 3rd quarter. Summit Global Investments now owns 16,549 shares of the biopharmaceutical company’s stock valued at $2,467,000 after acquiring an additional 4,837 shares in the last quarter. MGO One Seven LLC lifted its stake in Gilead Sciences by 31.0% during the third quarter. MGO One Seven LLC now owns 17,858 shares of the biopharmaceutical company’s stock worth $2,662,000 after purchasing an additional 4,231 shares during the last quarter. Finally, Americana Partners LLC bought a new position in Gilead Sciences during the third quarter worth $369,000. Institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Insider Buying and Selling at Gilead Sciences

In related news, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the transaction, the chief executive officer directly owned 577,133 shares of the company’s stock, valued at $85,785,049.12. The trade was a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 111,000 shares of company stock valued at $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GILD shares. HSBC lifted their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Citigroup increased their target price on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a report on Friday. BMO Capital Markets restated an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a research report on Friday. Bank of America lifted their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a report on Tuesday, October 20th. Finally, Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $169.19.

Gilead Sciences Trading Up 3.1%

NASDAQ:GILD opened at $170.68 on Friday. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $175.65. The firm has a market capitalization of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The business has a 50 day simple moving average of $150.87 and a 200 day simple moving average of $139.79.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period last year, the company earned $2.47 earnings per share. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post -1.03 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio is currently -103.80%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.